Figure 3

Computed tomography scans. A) at baseline, B) 2 months, and, C) 3.8 months after treatment initiation with a combination of a MEK and BRAF inhibitor, of a patient (case #8) with short-lived CR (TTF = 5.6 months), who demonstrated an NRAS mutation in a biopsy obtained 3.8 months after treatment initiation. At 2 months, the liver lesion has regressed; at 3.8 months it recurred.